IP Verse

Cyclic Ntcp-Targeting Peptides And Their Uses As Entry Inhibitors - EP3389691

The patent EP3389691 was granted to Ruprecht Karls Universitt Heidelberg on May 6, 2020. The application was originally filed on Dec 15, 2016 under application number EP16822406A. The patent is currently recorded with a legal status of "Revoked".

EP3389691

RUPRECHT KARLS UNIVERSITT HEIDELBERG
Application Number
EP16822406A
Filing Date
Dec 15, 2016
Status
Revoked
Jul 18, 2025
Publication Date
May 6, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONFeb 5, 2021MEWBURN ELLISADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2009092612
INTERNATIONAL-SEARCH-REPORTWO2012107579
OPPOSITIONWO2009092612
OPPOSITIONWO2012107579

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- R C Kennedy ET AL, "Inhibition of a common human anti-hepatitis B surface antigen idiotype by a cyclic synthetic peptide", Journal of Virology, UNITED STATES, (19830501), pages 653 - 655, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC255172/pdf/jvirol00146-0329.pdf, (20160311), XP055257546 [Y] 1-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- BROWN S E ET AL, "Determination of the affinity of antibodies to hepatitis B surface antigen in human sera", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 72, no. 1, doi:10.1016/0022-1759(84)90431-9, ISSN 0022-1759, (19840803), pages 41 - 48, (19840803), XP025425108 [Y] 1-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- LEVENGOOD M R ET AL, "Use of lantibiotic synthetases for the preparation of bioactive constrained peptides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 10, doi:10.1016/J.BMCL.2008.01.062, ISSN 0960-894X, (20080515), pages 3025 - 3028, (20080119), XP022669491 [Y] 1-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MASAHARU SOMIYA ET AL, "Intracellular trafficking of bio-nanocapsule-liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein", JOURNAL OF CONTROLLED RELEASE., NL, (20150612), vol. 212, doi:10.1016/j.jconrel.2015.06.012, ISSN 0168-3659, pages 10 - 18, XP055257568 [Y] 1-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- STEPHAN URBAN ET AL, "Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes", GASTROENTEROLOGY, (20140701), vol. 147, no. 1, doi:10.1053/j.gastro.2014.04.030, ISSN 0016-5085, pages 48 - 64, XP055175233 [YD] 1-15 * the whole document * * figure 2 *
INTERNATIONAL-SEARCH-REPORT- DANIELLE A GUARRACINO, "Wheel of Fortune - Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics", CURRENT CHEMICAL BIOLOGY, (20150401), vol. 9, no. 1, doi:10.2174/2212796809666150911201950, pages 36 - 52, XP055252227 [Y] 1-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- Do-Hyoung Kim ET AL, "An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus", BMB Reports, doi:10.5483/BMBRep.2008.41.9.640, (20080930), pages 640 - 644, URL: http://www.bmbreports.org/jbmb/jbmb_files/[41-9]0809300832_(640-644)BMB105(08-106).pdf, (20160311), XP055257576 [Y] 1-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MICHELLE A CAMERINO ET AL, "Computer-assisted design of cyclic peptides and peptidomimetics", CHIMICA OGGI., IT, (20080901), vol. 26, no. 5, doi:https://www.researchgate.net/publication/232716656_Computer-assisted_design_of_cyclic_peptides_and_peptidomimetics, ISSN 0392-839X, pages 46 - 51, XP055252262 [Y] 1-15 * the whole document *
OPPOSITION- AKCAN et al., "Conotoxin-based Leads in Drug Design", Peptide Drug Discovery and Development: Translational Research in Academia and Industry, (20110000), pages 119 - 137, XP055788214
OPPOSITION- ANDREOTTI et al., "Structural Determinants of Salmon Calcitonin Bioactivity", J. Biol. Chem., (20060000), vol. 281, no. 34, pages 24193 - 24203, XP055788253
OPPOSITION- ATKINSON et al., "Structural and Dynamic Characterization of ö-Conotoxin MVIIA: The Binding Loop Exhibits Slow Conformational Exchange", Biochemistry, (20000000), vol. 39, pages 3908 - 3919, XP055788257
OPPOSITION- JENSEN et al., "Cyclisation increases the stability of the sea anemone peptide APETx2 but decreases its activity at acid-sensing ion channel 3", Mar. Drugs, (20120000), vol. 10, pages 1511 - 1527, XP055788240
OPPOSITION- KAZANTZIS et al., "Conformationally constrained human calcitonin (hCt) analogues reveal a critical role of sequence 17-21 for the oligomerization state and bioactivity of hCt", Eur. J. Biochem., (20020000), vol. 269, pages 780 - 791, XP055788245
OPPOSITION- KENNEDY et al., "Inhibition of a common human anti-hepatitis B surface antigen idiotype by a cyclic synthetic peptide", Journal of Virology, (19830501), pages 653 - 655, XP055257546
OPPOSITION- ROSE et al., "Crystal structure of the neurophysin-oxytocin complex", Nature Structural Biology, (19960000), vol. 3, no. 2, pages 163 - 169, XP055788261
OPPOSITION- TAPEINOU et al., "Cyclic Peptides on a Merry-Go-Round; Towards Drug Design", Peptide Science, (20150405), vol. 104, no. 5, pages 453 - 461, XP055788192
OPPOSITION- BROWN et al., "Determination of the affinity of antibodies to hepatitis B surface antigen in human sera", J. Immunol. Methods, (19840803), vol. 72, no. 1, pages 41 - 48, XP025425108
OPPOSITION- LEVENGOOD et al., "Use of lantibiotic synthetases for the preparation of bioactive constrained peptides", Biorganic and Medicinal Chemistry Letters, (20080515), vol. 18, no. 10, pages 3025 - 3028, XP022669491
OPPOSITION- SOMIYA et al., "Intracellular trafficking of bionanocapsule-liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein", J. Controlled Release, (20150612), vol. 212, pages 10 - 18, XP055257568
OPPOSITION- URBAN et al., "Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes", Gastroenterology, (20140701), vol. 147, no. 1, pages 48 - 64, XP055175233
OPPOSITION- SCHULZE et al., "Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction", J. Virol., (20100000), vol. 84, no. 4, doi:10.1128/JVI.01902-09, pages 1989 - 2000, XP055252335
OPPOSITION- GUARRACINO, "Wheel of Fortune - Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics", Current Chemical Biology, (20150401), vol. 9, no. 1, pages 36 - 52, XP055252227
OPPOSITION- DO-HYOUNG KIM et al., "An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus", BMB Reports, (20080930), pages 640 - 644, XP055257576
OPPOSITION- CAMERINO et al., "Computer-assisted design of cyclic peptides and peptidomimetics", Chimica Oggi, (20080901), vol. 26, no. 5, pages 46 - 51, XP055252262

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents